Trials / Completed
CompletedNCT00168181
Trial Comparing Oral Pilocarpine (Salagen) Versus Submandibular Salivary Gland Transfer Protocol, For the Prevention of Radiation (XRT) Induced Xerostomia in Head and Neck Cancer Patients
A Phase III Randomized Trial Comparing Oral Pilocarpine (Salagen) Versus Submandibular Salivary Gland Transfer Protocol, For the Prevention of Radiation (XRT) Induced Xerostomia in Head and Neck Cancer Patients
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 220 (estimated)
- Sponsor
- Alberta Health services · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a study to see whether the drug Salagen or salivary gland transfer is better for the prevention of dryness of the mouth in patients with head and neck cancer receiving radiation treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Submandibular gland Transfer | |
| DRUG | Salagen |
Timeline
- Start date
- 2002-04-01
- Completion
- 2008-04-01
- First posted
- 2005-09-15
- Last updated
- 2011-04-18
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT00168181. Inclusion in this directory is not an endorsement.